Protein Binding and Kinetics of Drugs in Liver Diseases

Clinical Pharmacokinetics

Volumn 2, Issue 1, 1977, Pages 32-44

  Blaschke, Terrence F ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOBARBITAL; CHLORAMPHENICOL; CHLORPROMAZINE; CLINDAMYCIN; DEXTROPROPOXYPHENE; DIAZEPAM; DIGITOXIN; HEXOBARBITAL; INDOCYANINE GREEN; LIDOCAINE; MORPHINE; NORTRIPTYLINE; PARACETAMOL; PENTAZOCINE; PETHIDINE; PHENAZONE; PHENYTOIN; PROPRANOLOL; QUINIDINE; THEOPHYLLINE; THIOPENTAL; TOLBUTAMIDE; WARFARIN;

DRUG DISTRIBUTION; DRUG METABOLISM; DRUG PROTEIN BINDING; LIVER DISEASE; MATHEMATICAL MODEL; MODEL; PHARMACOKINETICS;

ABSORPTION; BIOTRANSFORMATION; BLOOD PROTEINS; HALF-LIFE; HUMAN; KINETICS; LIVER; LIVER DISEASES; MODELS, BIOLOGICAL; PHARMACEUTICAL PREPARATIONS; PROTEIN BINDING; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0017345066     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.2165/00003088-197702010-00003     Document Type: Article

References (98)

1. The protein binding of some drugs in plasma from patients with alcoholic liver disease
2. Clearance of Antipyrine-dependence of quantitative liver function
3. Comparison of plasma levels of antipyrine, tolbutamide, and warfarin after oral and intravenous administration
4. Elimination of chloramphenicol and thiamphenicol in subjects with cirrhosis of the liver
5. Die vekikelfunction der bluteiweisskorper
6. Relationship of pentazocine plasma levels to pharmacologic activity in man
7. Liver disease and drug therapy in ‘symposium on Individualisation of drug therapy’
8. Influence of acute viral hepatitis on Phenytoin kinetics and protein binding
9. Plasma protein binding of tricyclic antidepressants in man
10. The clearance of antipyrine and indocyanine green in normal subjects and in patients with chronic liver disease
11. A study of factors influencing drug disposition in chronic liver disease, using the model drug (+)-propranolol
12. The disposition of propranolol VIII. General implications of the effects of liver blood flow on elimination from the perfused rat liver
13. Increased clearance of antipyrine and d-propranolol after phenobarbital treatment in the monkey. Relative contributions of enzyme and induction and increased hepatic blood flow
14. Pathophysiological factors influencing drug kinetics
15. Pharmacokinetics of hexobarbital in acute hepatitis and after apparent recovery
16. The fate of thiopental in man and a method for its estimation in biological material
17. Morphine metabolism in man
18. Data point weighting in pharmacokinetic analysis: intravenous paracetamol in man
19. Metabolic interactions among environmental chemicals and drugs
20. Pharmacokinetics in the elderly
21. Plasma protein binding of chlorpromazine
22. Influence of binding on drug metabolism and distribution
23. Drug dosage in renal disease
24. The binding capacity of albumin and renal disease
25. The disposition of propranolol III: decreased half-life and volume of distribution as a result of plasma binding in man, monkey, dog, and rat
26. Disposition of propranolol VI: independent variation in steady-state circulating drug concentrations and half-life as a result of plasma drug binding in man
27. Pharmacokinetics of saturably metabolised amobarbital
28. The binding of paracetamol to plasma proteins of man and pig
29. Plasma protein binding of thiopental in patients with impaired renal or hepatic function
30. Factors affecting drug metabolism
31. Overview of drug-protein binding
32. Biochemical studies on chloramphenicol II. Tissue distribution and excretion studies
33. The interactions of drugs and plasma proteins
34. Gordon, R.C.; Regamey, C. and Kirby, W.M.M.: Serum protein binding of erythromycin, lincomycin and clindamycin. Journal of Pharmacology and Science 1074–1077 (1973).
35. First pass metabolism of nortriptyline in man
36. Reciprocal relation between plasma albumin level and hepatic sulfobromophthalein removal
37. Clinical toxicity of chlordiazepoxide and diazepam in relation to serum albumin concentration: a report from the Boston Collaborative Drug Surveillance Program
38. Effect of portocaval shunt on the disposition of drugs with and without first pass effect
39. Pharmacokinetik von Glymidine (Glycodiazin) and tolbutamid bei akuten und chronischen lebershaden
40. 14C-aminopyrine
41. Use of clindamycin in patients with liver disease
42. Plasma protein binding of diphenyl-hydantoin. Effects of sex hormones, renal and hepatic disease
43. Effect of smoking on theophylline disposition
44. Pharmacokinetics of theophylline: application to adjustment of the clinical dose of aminophylline
45. Plasma and tissue protein binding of drugs in pharmacokinetics
46. Comparative drug elimination capacity in man — glutethimide amobarbital, antipyrine and sulfinpyrazone
47. Correlation of aryl hydrocarbon hydroxylase activity of human lymphocyte cultures and plasma elimination rates for antipyrine and phenylbutazone
48. Pathophysiological and disease-induced changes in drug distribution volume: Pharmacokinetic implications
49. The effects of age and liver disease on the disposition and elimination of diazepam in adult man
50. The effect of cirrhosis on the disposition and elimination of meperidine in man
51. Binding of drugs to serum albumin
52. Relationship between theophylline concentration in plasma and saliva of man
53. Phenylbutazone and isoniazid metabolism in patients with liver disease in relation to previous drug therapy
54. Pharmacokinetics of ampicillin in cirrhosis
55. Binding of digitoxin and some related cardenolides to human plasma proteins
56. Meperidine kinetics in man. Intravenous injection in surgical patients and volunteers
57. Metabolism of amylobarbitone in patients with chronic liver disease
58. Plasma disappearance and cerebral effects of chlorpromazine in cirrhosis
59. Effect of acute viral hepatitis on the disposition and elimination of meperidine
60. Chlordiazepoxide (Librium) therapy in hepatic insufficiency (Abstract)
61. The binding of drugs by plasma proteins
62. Hemodynamic drug interactions: the effects of altering hepatic blood flow on drug disposition
63. Altered hepatic blood flow and drug disposition
64. Morphine binding to human plasma proteins
65. Morphine and Phenytoin binding to plasma proteins in renal and hepatic failure
66. Pharmacokinetics of warfarin following intravenous administration to man
67. Clearance and biologic half life as indices of intrinsic hepatic metabolism
68. Pharmacokinetic drug interactions
69. Plasma protein binding of diphenylhydantoin in normal and hyperbilirubinemic infants
70. The binding of drugs to plasma proteins from patients with poor renal function
71. Influence of disease on binding of drugs to plasma proteins
72. Effect of route of administration of drug disposition
73. Clearance concepts in pharmacokinetics
74. Pharmacokinetics in disease states modifying hepatic and metabolic function
75. The effect of barbiturates in patients with liver disease
76. Effects of route of administration and blood flow on hepatic drug elimination
77. Normal disposition of oxazepam in acute viral hepatitis and cirrhosis
78. The use of antipyrine in the measurement of total body water in man
79. Paradoxical urinary excretion of d-glucaric acid in acute viral hepatitis
80. Plasma protein binding of diazepam and tolbutamide in chronic alcoholics
81. Diazepam and paraldehyde for treatment of severe delirium tremens: a controlled trial
82. Lidocaine pharmacokinetics in advanced heart failure, liver disease, and renal failure in humans
83. Pharmacokinetics in the aged: A review
84. Binding of anilide-type local anesthetics in human plasma
85. Absolute quinidine bioavailability
86. Metabolism and excretion of digitoxin in man
87. The distribution of phenobarbital
88. Decreased drug binding in serum from patients with chronic hepatic disease
89. A physiological approach to hepatic drug clearance
90. Drug disposition and liver disease
91. Influence of acute viral hepatitis on disposition and pharmacologic effect of warfarin
92. Influence of viral hepatitis on the disposition of two compounds with high hepatic clearance: ligocaine and indocyanine green
93. Influence of acute viral hepatitis on disposition and plasma binding of tolbutamide (Abstract)
94. Antipyrine and indocyanine green as indicators of drug disposition during acute viral hepatitis (Abstract)
95. Concentration of propoxyphene in human plasma following oral, intramuscular and intravenous administration
96. Serum protein binding as a determinant of warfarin body clearance and anticoagulant effect